Non-invasive advanced image analysis could lead to better patient care
TGen, Scottsdale Healthcare, and Cancer Centers of America are leading new research studies for patients suffering with lung cancer.
Method for validating radiobiological samples using a linear accelerator
Abstract There is an immediate need for rapid triage of the population in case of a large scale exposure to ionizing radiation. Knowing the dose absorbed by the body will allow clinicians to administer medical treatment for the best chance… Read More
Imaging Endpoints develops predictor of response for Tracon Pharmaceuticals
SAN DIEGO (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, a biopharmaceutical company that develops targeted therapies for oncology and ophthalmology, today announced data being presented on TRC105 during two poster presentations at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer… Read More
Imaging Endpoints’ Expertise in Molecular Imaging Highlighted in Imaging Economics
With the push for integrative health and collaborative care, now more than ever radiologists are serving in roles that transcend pure diagnostician. In an oncology specialty that espouses a multimodality, team-based approach, imaging is poised to fulfill, and go beyond,… Read More
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging
Abstract Objective To evaluate the performance characteristics of florbetapir F18 positron emission tomography (PET) in patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and healthy control subjects (HCs). Methods Florbetapir PET was acquired in 184 subjects (45 AD patients,… Read More
Imaging Endpoints’ CMO Ron Korn Recognized: New England Journal of Medicine hails new skin cancer drug as ‘greatest advance yet’
SCOTTSDALE, Ariz. — Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen"… Read More
Ronald L. Korn, M.D., PhD., founder and CEO of Imaging Endpoints
Ron Korn, M.D. of Imaging Endpoints was recently asked about his team’s work toward the integration of imagery into drug discovery and development. While full integration is a thing of the future, the use of imagery in drug discovery and development can lend significant insights into the biology and efficacy of a drug.
Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors
Abstract Progression-free survival (PFS) is increasingly used as an important and even a primary endpoint in randomized cancer clinical trials in the evaluation of patients with solid tumors for both practical and clinical considerations. Although in its simplest form, PFS… Read More
Interpretation of PET Scans: Do Not Take SUVs at Face Value
To read more click here Weiss G.J. and Korn R.L. “Interpretation of PET Scans: Do Not Take SUVs at Face Value.” J Thor Onc., 7(12): 1744-45, (2012).
Metastatic Basal Cell Carcinoma in the Era of Hedgehog Signaling Pathway Inhibitors
BACKGROUND: Inhibition of the hedgehog signaling pathway (HHSP) for the treatment of locally advanced basal cell carcinoma (BCC) and metastatic BCC (mBCC) has produced promising results. Typically, mBCC is not taken into consideration during the workup of a patient with… Read More
